Can I Take Vitamin B12 with Evenity (Romosozumab)?

The Short Answer: Vitamin B12 Is Safe to Take with Evenity

Vitamin B12 does not interfere with how romosozumab works. Romosozumab binds sclerostin, a protein that suppresses bone formation, and blocking it increases osteoblast activity while transiently reducing osteoclast activity. This dual mechanism is entirely protein-mediated and does not involve the metabolic pathways that handle water-soluble vitamins.

Vitamin B12 (cobalamin) is absorbed in the terminal ileum via intrinsic factor, transported by transcobalamin II, and stored in the liver. None of those steps overlap with the subcutaneous depot pharmacokinetics of romosozumab. The FDA-approved prescribing information for romosozumab lists no interactions with vitamins or nutritional supplements.

Why Patients Ask This Question

The confusion often arises because osteoporosis patients are frequently older, take multiple medications, and may be on metformin for type 2 diabetes. Metformin has a well-documented ability to reduce B12 absorption over time, which creates a legitimate clinical concern. The concern is about metformin, not about romosozumab itself.

A second source of confusion is that calcium and vitamin D are specifically required alongside Evenity per its label. Patients reasonably wonder whether other supplements, including B12, carry similar directives or cautions.

How Romosozumab Works and Why B12 Does Not Affect It

Sclerostin Inhibition Explained

Romosozumab is a monoclonal antibody that targets sclerostin, a glycoprotein encoded by the SOST gene and secreted by osteocytes. Sclerostin inhibits the Wnt signaling pathway, which is the primary driver of osteoblast differentiation and bone matrix production. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP rises roughly 145% above baseline within one month) and decreases bone resorption markers (CTX falls roughly 55% below baseline). This dual effect is unique among approved osteoporosis therapies.

The drug is dosed as two 105 mg subcutaneous injections (total 210 mg) once monthly for exactly 12 months, then followed by antiresorptive therapy.

Vitamin B12 Metabolism Runs on a Separate Track

Cobalamin is a water-soluble vitamin. After oral ingestion it binds to intrinsic factor secreted by gastric parietal cells, and that complex is absorbed by cubilin receptors in the terminal ileum. This absorption mechanism depends on gastric acid, intrinsic factor sufficiency, and intestinal integrity, none of which romosozumab touches.

Once absorbed, B12 is carried by transcobalamin II to target tissues, where it acts as a cofactor for methionine synthase (converting homocysteine to methionine) and methylmalonyl-CoA mutase (converting methylmalonyl-CoA to succinyl-CoA). Deficiency in these reactions leads to megaloblastic anemia and peripheral neuropathy. Romosozumab has no role in either enzyme system.

The Real Clinical Issue: Metformin-Induced B12 Depletion in Osteoporosis Patients

This is where the clinical nuance matters. Many patients prescribed romosozumab are postmenopausal women with comorbidities, including type 2 diabetes managed with metformin.

How Metformin Depletes B12

Metformin reduces B12 absorption by interfering with calcium-dependent binding of the intrinsic factor-B12 complex to cubilin receptors in the ileum. A landmark analysis of the Diabetes Prevention Program Outcomes Study (DPPOS) found that metformin use was associated with a significantly higher prevalence of B12 deficiency compared to placebo (P<0.001), with deficiency rates rising with duration of use. Long-term metformin users (more than 4 years) showed deficiency rates approaching 30% in some cohorts.

The American Diabetes Association Standards of Care state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with peripheral neuropathy or anemia."

Why This Matters Alongside Romosozumab

Romosozumab itself does not worsen B12 depletion. However, if a patient starts Evenity while unknowingly B12-deficient (due to years of metformin), symptoms of neuropathy may emerge or worsen during the 12-month Evenity course. A clinician who is unaware of the patient's B12 status might attribute neurological symptoms to the new drug rather than the pre-existing deficiency.

Checking a baseline serum B12 (and methylmalonic acid if borderline) before starting Evenity in any metformin user takes one blood draw and can prevent diagnostic confusion later.

The table below summarizes when to check B12 in the context of starting romosozumab:

| Patient profile | B12 check before Evenity? | Supplementation? | |---|---|---| | No metformin, adequate diet | Not routinely required | Maintain RDA 2.4 mcg/day | | Metformin <1 year, asymptomatic | Consider checking | Replace if <300 pg/mL | | Metformin >2 years, any dose | Recommended | Replace if <300 pg/mL | | Metformin + PPI or H2 blocker | Strongly recommended | Replace if <400 pg/mL (higher threshold with absorption impairment) | | Vegan or vegetarian diet | Recommended | Supplement routinely regardless of labs | | Prior bariatric surgery | Required | Lifelong B12 supplementation per AACE guidelines |

Vitamin B12 Deficiency: Recognizing It and Treating It

Symptoms That Should Prompt Testing

B12 deficiency produces a recognizable constellation of signs. Neurological features include paresthesias (tingling or numbness, typically symmetrical in hands and feet), proprioceptive loss, and in severe cases subacute combined degeneration of the spinal cord. NHANES data indicate that roughly 3.2% of adults over 50 have frank B12 deficiency (serum B12 <200 pg/mL), and another 20% have borderline-low levels (200 to 300 pg/mL).

Hematologic signs include macrocytic, megaloblastic anemia with hypersegmented neutrophils on peripheral smear. Fatigue and cognitive slowing can appear before anemia becomes overt.

Serum B12 Versus Functional Markers

Serum cobalamin is a useful first-line screen but has known limitations. It can appear falsely normal in patients with high haptocorrin (transcobalamin I) binding, for example in myeloproliferative disease. Methylmalonic acid (MMA) and homocysteine are more sensitive functional markers. MMA above 0.4 micromol/L indicates tissue-level deficiency even when serum B12 is within the low-normal range.

Oral vs. Intramuscular Repletion

High-dose oral cyanocobalamin (1,000 mcg daily) is as effective as intramuscular injection for most patients with dietary or metformin-related deficiency, because roughly 1% of an oral dose is absorbed by passive diffusion, independent of intrinsic factor. A Cochrane review of oral vs. Intramuscular B12 found that oral high-dose therapy achieved similar hematological and neurological outcomes to intramuscular dosing at 90 and 120 days. Intramuscular dosing remains preferred for patients with intrinsic factor antibodies, severe neurological involvement, or post-ileal-resection anatomy.

Bone Health, Homocysteine, and an Indirect Argument for Adequate B12

There is a biologically plausible, if indirect, reason to pay extra attention to B12 status in patients being treated for osteoporosis. B12 deficiency raises plasma homocysteine. Elevated homocysteine has been associated with increased fracture risk, possibly through impaired collagen cross-linking in bone matrix.

The Framingham Osteoporosis Study found that men in the highest quartile of plasma homocysteine had roughly a 4-fold higher hip fracture risk compared to those in the lowest quartile (hazard ratio approximately 3.8, 95% CI 1.5 to 9.8). A separate Dutch cohort reported a similar 1.9-fold increased fracture risk per standard deviation rise in homocysteine in women over 55.

This does not mean B12 supplementation prevents fractures in otherwise replete patients. Current evidence does not support that conclusion. However, in a patient already on romosozumab specifically to reduce fracture risk, allowing preventable homocysteine elevation from untreated B12 deficiency seems clinically avoidable.

Evenity's Efficacy Data: What You're Protecting

FRAME Trial Results

Understanding why B12 status matters during Evenity therapy requires appreciating what the therapy accomplishes. In the FRAME trial (N=7,180), romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% versus placebo (P<0.001). Clinical fracture risk fell by 36% (P<0.001). These are among the largest fracture-risk reductions seen in any osteoporosis trial.

After the 12-month Evenity course, patients transitioned to denosumab (60 mg every 6 months), and vertebral fracture protection was maintained at 24 months.

ARCH Trial and the Cardiovascular Signal

The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone. Romosozumab reduced vertebral fractures by 48% and hip fractures by 38% at 24 months. However, a numerical imbalance in major adverse cardiovascular events (1.9% romosozumab vs. 1.4% alendronate) prompted the boxed warning now on the label. Romosozumab is contraindicated within 12 months of a myocardial infarction or stroke. B12 has no bearing on this cardiovascular concern.

Practical Guidance for Patients Already Taking Both

If you are currently taking vitamin B12 and starting Evenity, no dose separation or timing adjustment is needed. The two have no pharmacokinetic interaction. Take B12 whenever it fits your routine.

If your Evenity prescription comes alongside metformin (or you added metformin during the 12-month Evenity course), ask your prescriber to check a serum B12 and MMA at baseline and again at 6 to 12 months. If serum B12 falls below 300 pg/mL, a supplement of 1,000 mcg oral cyanocobalamin daily is a reasonable starting point. The NIH Office of Dietary Supplements notes that most adults tolerate high-dose oral B12 without adverse effects, because absorption is self-limiting and excess is renally cleared.

Calcium (1,000 to 1,200 mg daily from diet and supplements combined) and vitamin D (at least 600 to 800 IU daily, often 1,000 to 2,000 IU in practice) remain required co-therapies per the Evenity prescribing information. Neither calcium nor vitamin D interacts with B12 at physiological doses.

Monitoring Summary During the 12-Month Evenity Course

Regular lab monitoring makes the 12-month treatment window more useful. A practical monitoring schedule might include:

• Baseline: bone turnover markers (P1NP, CTX), serum calcium, 25-OH vitamin D, renal function, serum B12 (if metformin user or risk factors for deficiency present)
• Month 1 to 3: calcium and vitamin D status if dietary intake is uncertain
• Month 6: repeat B12 in any patient on metformin, PPI, or with symptoms of neuropathy
• Month 12 (end of Evenity course): full bone panel, transition planning to antiresorptive agent

Bone density (DXA) is typically repeated at 12 to 24 months rather than mid-course, per standard osteoporosis management guidelines from the Endocrine Society.